Targeted agents for adjuvant therapy of colon cancer

被引：21

作者：

de Gramont, Aimery

Tournigand, Christophe

Andre, Thierry

Larsen, Annette K.

Louvet, Christophe

机构：

[1] Hop St Antoine, Serv Med Interne Oncol, F-75571 Paris 12, France

[2] Grp Cooperateur Multidisciplinaire Oncol, GERCOR, Paris, France

来源：

SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 06期

关键词：

D O I：

10.1053/j.seminoncol.2006.10.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant therapy for colorectal cancer consists primarily of combinations of 5-fluorouracil/leucovorin (5-FU/LV) (with infusional or bolus 5-FU) with oxaliplatin or oral capecitabine. The angiogenesis inhibitor bevacizumab and the epidermal growth factor receptor inhibitor cetuximab have shown activity when combined with 5-FU/LV-based regimens as first-line treatment of advanced disease and are currently being evaluated as part of adjuvant therapy in colon cancer. Bevacizumab is being evaluated in combination with FOLFOX4 (5-FU/LV/oxaliplatin), FOLFOX6, or XELOX (capecitabine/oxaliplatin) in the National Surgical Adjuvant Breast and Bowel Project C08 trial, the AVANT (AVastin adjuvANT) trial, and the Intergroup Rectal Adjuvant trial. Cetuximab is being evaluated in combination with FOLFOX4 and FOLFOX6 in the North Central Cancer Treatment Group (NCCTG) N0147 trial and the Pan European Trials in Adjuvant Colon Cancer (PETTAC) 8 trial. © 2006 Elsevier Inc. All rights reserved.

引用

页码：S42 / S45

页数：4

共 15 条

[1] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[2] Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer:: Results of a randomized trial [J].

André, T ;

Colin, P ;

Louvet, C ;

Gamelin, E ;

Bouche, O ;

Achille, E ;

Colbert, N ;

Boaziz, C ;

Piedbois, P ;

Tubiana-Mathieu, N ;

Boutan-Laroze, A ;

Flesch, M ;

Buyse, M ;

de Gramont, A .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2896-2903

[3]

de Gramont A, 2005, J CLIN ONCOL, V23, p246S

[4] Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: Final report of Intergroup 0089 [J].

Haller, DG ;

Catalano, PJ ;

Macdonald, JS ;

O'Rourke, MA ;

Frontiera, MS ;

Jackson, DV ;

Mayer, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8671-8678

[5] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[6]

LABIANCA R, 1995, LANCET, V345, P939

[7]

MOERTEL CG, 1990, NEW ENGL J MED, V322, P399

[8] Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer [J].

OConnell, MJ ;

Mailliard, JA ;

Kahn, MJ ;

MacDonald, JS ;

Haller, DG ;

Mayer, RJ ;

Wieand, HS .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :246-250

[9]

Saltz LB, 2004, P AN M AM SOC CLIN, V23, P246

[10]

TABERNERO J, 2004, P AN M AM SOC CLIN, V23, pS1092

← 1 2 →